Prometheus Biosciences Operating Income

As of the most recent data (March 2023), RXDX shows a operating income of $-160M. That compares with $-110M in the prior-year period — down 50.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RXDX's operating income is now $-160M (was $-110M) — a 50.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Prometheus Biosciences is outperforming or lagging.

Tracking RXDX's operating income over time shows whether Prometheus Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-160M That compares with $-110M in the prior-year period — down 50.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Prometheus Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-160M) with ownership activity and broader fundamentals.

Prometheus Biosciences's operating income is $-160M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.